Esculetin inhibits endometrial cancer proliferation and promotes apoptosis via hnRNPA1 to downregulate BCLXL and XIAP

Jiang, Ru-Qi; Su, Guifeng; Chen, Xi; Chen, Shuo; Li, Qianhui; Xie, Bumin; Zhao, Yang

doi:10.1016/j.canlet.2021.08.039

Cited by 25 publications

(29 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…207 Protein crotonylation in the regulation of oncogenic signaling: Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) is highly expressed in a variety of cancers and closely associated with cancer initiation and progression. [208][209][210] P300-mediated lysine crotonylation of HNRNPA1 helps to upregulate its protein expression, which in turn promotes HeLa cell proliferation, invasion, and migration. 211 However, whether crotonylation hampered HNRNPA1 ubiquitination and degradation to enhance its protein stability still needs to be investigated.…”

Section: Protein Crotonylation and Its Role In Human Diseasesmentioning

confidence: 99%

Protein acylation: mechanisms, biological functions and therapeutic targets

Shang

Liu

Hua

2022

Sig Transduct Target Ther

View full text Add to dashboard Cite

Metabolic reprogramming is involved in the pathogenesis of not only cancers but also neurodegenerative diseases, cardiovascular diseases, and infectious diseases. With the progress of metabonomics and proteomics, metabolites have been found to affect protein acylations through providing acyl groups or changing the activities of acyltransferases or deacylases. Reciprocally, protein acylation is involved in key cellular processes relevant to physiology and diseases, such as protein stability, protein subcellular localization, enzyme activity, transcriptional activity, protein–protein interactions and protein–DNA interactions. Herein, we summarize the functional diversity and mechanisms of eight kinds of nonhistone protein acylations in the physiological processes and progression of several diseases. We also highlight the recent progress in the development of inhibitors for acyltransferase, deacylase, and acylation reader proteins for their potential applications in drug discovery.

show abstract

Section: Protein Crotonylation and Its Role In Human Diseasesmentioning

confidence: 99%

Protein acylation: mechanisms, biological functions and therapeutic targets

Shang

Liu

Hua

2022

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…Binding to the C-terminal region of hnRNPA1, quercetin hindered hnRNPA1’s combination with transportin 1 (Tnpo1), leading to its cytoplasmic retention and subsequent recruitment of hnRNPA1 to stress granules (SGs), ultimately putting cancer cells on the path to apoptosis [ 68 ]. Meanwhile, esculetin, a coumarin derivative from several herbs, was shown to induce apoptosis of endometrial cancer cells by affecting the nucleocytoplasmic transport of the hnRNPA1-BCLXL/XIAP mRNA complex [ 69 ]. Additionally, hnRNPA1-specific single-stranded DNA aptamer, BC15, was developed as a potential drug candidate for hepatocarcinoma treatment [ 70 ].…”

Section: The Roles Of Hnrnpa/b In Cancers: Molecular Mechanisms and C...mentioning

confidence: 99%

Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets

Wang

et al. 2022

Cell Death Discov.

View full text Add to dashboard Cite

Heterogeneous nuclear ribonucleoprotein A/B (hnRNPA/B) is one of the core members of the RNA binding protein (RBP) hnRNPs family, including four main subtypes, A0, A1, A2/B1 and A3, which share the similar structure and functions. With the advance in understanding the molecular biology of hnRNPA/B, it has been gradually revealed that hnRNPA/B plays a critical role in almost the entire steps of RNA life cycle and its aberrant expression and mutation have important effects on the occurrence and progression of various cancers. This review focuses on the clinical significance of hnRNPA/B in various cancers and systematically summarizes its biological function and molecular mechanisms.

show abstract

“…Esculetin is a coumarin derivative that suppresses endometrial cancer proliferation and induces apoptosis by downregulating the BCLXL and XIAP via hnRNPA1. Its anticancer actions have been analyzed in vivo in nude mouse xenograft models of human endometrial cancer ( Jiang et al, 2021 ).…”

Section: Natural Kinase Inhibitors For Management Of Endometrial/uter...mentioning

confidence: 99%

Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies

et al. 2022

View full text Add to dashboard Cite

Endometrial cancer (EC) is the sixth most prevalent type of cancer among women. Kinases, enzymes mediating the transfer of adenosine triphosphate (ATP) in several signaling pathways, play a significant role in carcinogenesis and cancer cells’ survival and proliferation. Cyclin-dependent kinases (CDKs) are involved in EC pathogenesis; therefore, CDK inhibitors (CDKin) have a noteworthy therapeutic potential in this type of cancer, particularly in EC type 1. Natural compounds have been used for decades in the treatment of cancer serving as a source of anticancer bioactive molecules. Many phenolic and non-phenolic natural compounds covering flavonoids, stilbenoids, coumarins, biphenyl compounds, alkaloids, glycosides, terpenes, and terpenoids have shown moderate to high effectiveness against CDKin-mediated carcinogenic signaling pathways (PI3K, ERK1/2, Akt, ATM, mTOR, TP53). Pharmaceutical regimens based on two natural compounds, trabectedin and ixabepilone, have been investigated in humans showing short and midterm efficacy as second-line treatments in phase II clinical trials. The purpose of this review is twofold: the authors first provide an overview of the involvement of kinases and kinase inhibitors in the pathogenesis and treatment of EC and then discuss the existing evidence about natural products’ derived kinase inhibitors in the management of the disease and outline relevant future research.

show abstract

Esculetin inhibits endometrial cancer proliferation and promotes apoptosis via hnRNPA1 to downregulate BCLXL and XIAP

Cited by 25 publications

References 53 publications

Protein acylation: mechanisms, biological functions and therapeutic targets

Protein acylation: mechanisms, biological functions and therapeutic targets

Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets

Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies

Contact Info

Product

Resources

About